Skip to main content

Advertisement

Table 1 Comparison of patient demographics between groups

From: Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Variable Denosumab (n = 120) ZA (n = 122) P – value
Age (years) 64.9 ± 3.01 65.4 ± 3.44 0.19*a
Menopause age 53.1 ± 1.82 52.9 ± 1.78 0.43*a
Pathological types, No. 0.92*b
Invasive ductal carcinoma 97 98  
Other pathological types 23 24  
Tumor staging 0.95*c
I 53 57  
II 46 40  
III 21 25  
BMI (kg/m2) 24.4 ± 2.34 23.9 ± 2.36 0.11*a
BMD −2.30 ± 0.21 −2.33 ± 0.29 0.37*a
Personal history of fractures 15/120 19/122 0.49*b
Family history of fractures 17/120 18/122 0.90*b
  1. * No statistically significant values. a Analysed using an Independent-Samples t-test; b Analysed using the Chi-square test; c Analysed using the Mann-Whitney test. ZA: zoledronic acid; SSEs: symptomatic skeletal events; BMI: body mass index; BMD: bone mineral density